2026-07-10T18:30:00.000Z
Teleoperated Humanoid Robots Complete Live Surgery in a Medical World First
A humanoid robot that was never built to hold a scalpel held one steady inside a living animal's abdomen on July 8, 2026, and the incision worked. That's the plain version of a finding a team of engineers and surgeons at the University of California San Diego reported in Nature. The researchers completed two laparoscopic gallbladder removals on large non-primate mammals during a preclinical trial: one performed by a humanoid robot working alongside a human surgeon, the other by two humanoid robots operating together with no human at the table.
The result tests something no earlier surgical robotics study has tested in a live setting: whether a general-purpose robot built to walk and grasp broadly, not a machine built for one narrow task, can meet the precision surgery demands. A human surgeon directed every movement in both procedures from a console. Nothing about this study involved autonomous decision-making, and the authors are careful to say so.
What Happened
The Nature paper, titled "In vivo feasibility study of humanoid robots in surgery," comes from a team led by Zekai Liang and Michael Yip of UC San Diego's Jacobs School of Engineering, working with surgeons including Ryan Broderick and Shanglei Liu at the School of Medicine's Center for the Future of Surgery. The team built a teleoperation framework that let humanoid robots use standard laparoscopic instruments, tested through benchtop measurements, dry-lab exercises, and finally live porcine procedures. Custom adapters let the robots grip conventional surgical tools; nothing about the hardware was purpose-built for an operating room.
The robots, nicknamed "Surgie," stand about five feet tall and weigh roughly 60 pounds, a fraction of the size of a dedicated surgical robotic platform. A human surgeon controlled each robot's movements from a console for the full length of both procedures, with no autonomous action at any stage. The study is direct about its limits: this was a preclinical, controlled-environment trial on animal subjects, not human patients, and the robots needed recalibration multiple times mid-procedure, which stretched operating time well past what an established system would need.
Why This Is a Medical Milestone
The importance of this study sits in form factor, not autonomy. Conventional surgical robots, such as Intuitive Surgical's da Vinci Surgical System, are purpose-built machines that weigh close to 1,800 pounds and usually require a dedicated, retrofitted operating room. UC San Diego's team instead adapted a general-purpose humanoid robot, built for walking and object manipulation broadly, to a single, narrow surgical function. Every incision, grasp, and cut in both procedures was directed in real time by a human surgeon at a console.
Shanglei Liu, one of the paper's senior authors, said a procedure performed by a teleoperated humanoid was as precise as one performed with an established teleoperated system, while taking up a fraction of the room and cost. That is a different cost structure than anything sold into hospital surgical suites today, and it is the detail that should hold an investor's attention longer than the surgery itself. Earlier surgical robotics advances were mostly refinements to existing systems; this study tests a different architecture, and the authors themselves are candid that it remains unclear how close humanoid platforms are to matching the precision, control, and safety bar minimally invasive surgery requires.
Industry Impact
Surgical robotics now has two viable architectural paths instead of one, reflecting a broader evolution underway across the global humanoid robotics ecosystem, as detailed in kaiso research's global humanoid robot market report. Dedicated platforms such as da Vinci carry a two-decade regulatory track record; general-purpose humanoid systems offer a smaller, cheaper alternative that could, in principle, be repurposed across tasks well beyond the operating room. Manufacturers building single-function surgical robots may face competitive pressure from humanoid platform developers entering healthcare, alongside an opportunity to license instrumentation into that emerging space. For hospitals, the calculus is different too: a 60-pound machine needing no dedicated room modification is a different capital proposition than an 1,800-pound cart system.
Remote and field surgery is where the study's authors see the clearest near-term case. Michael Yip said the technology could reach remote communities facing staffing shortages and austere environments such as search-and-rescue field medicine. The study frames humanoid robots less as a replacement for surgeons than as a way to extend limited surgical expertise to more locations, with instrument handling as a likelier near-term use than incision-making itself.
A proof-of-concept Nature publication is an early-stage signal, not a commercialization event, but it is the kind of milestone that tends to pull capital toward humanoid-for-healthcare applications. Regulatory pathways for this category do not exist yet, and no humanoid surgical system has been submitted for clinical device clearance.
Challenges Before Human Adoption
Clinical validation on human patients hasn't started, and that gap is larger than any engineering fix on this list. Any future trials would need standard phased protocols under institutional and federal oversight, and a defined regulatory pathway for humanoid surgical platforms doesn't currently exist, because existing frameworks were built around single-purpose systems like da Vinci.
Reliability is the more immediate technical problem. The study's authors confirm that Surgie needed recalibration multiple times during both procedures, extending operating time well past established benchmarks. Latency, the lag between a surgeon's input and the robot's response, is a second unresolved issue the team is working to reduce, especially for longer-distance teleoperation.
Cybersecurity was not addressed in the published study, but it is a reasonable concern for any networked, remotely operated system built for field deployment. Surgeon training programs for humanoid teleoperation do not exist at scale yet, cost structures have not been disclosed, and questions about consent and liability in mixed human-robot teams remain open. None of these were resolved by the study; they are exactly what the authors flag as necessary before clinical deployment moves forward.
Kaiso Research Perspective
This is a genuine proof-of-concept, not a commercialization milestone, and stakeholders should calibrate their expectations to that distinction. Kaiso Research reads the finding as strong evidence that a general-purpose robotic form factor can execute laparoscopic tasks with precision approaching dedicated surgical systems, in a peer-reviewed setting. That is likely to accelerate early-stage investment across humanoid robotics' healthcare applications even though clinical deployment sits years away.
The industries most likely to benefit first are not hospital surgical departments but the adjacent use cases where a small footprint and low infrastructure need matter most: military and disaster-response field medicine, rural clinics, and remote or space-based operations, all referenced directly by the study's own authors. Inside hospitals, the nearer-term application looks like non-surgical assistance rather than autonomous or teleoperated incision-making.
On whether humanoid systems complement or replace existing surgical robots, the evidence points one way. Da Vinci and similar platforms carry two decades of regulatory history and precision advantages a five-year-old platform cannot match yet, so humanoid systems are far more likely to expand access where dedicated platforms were never affordable than to displace them in well-resourced centers. Before broader deployment becomes realistic, this dataset points to five gaps the field needs to close: fewer recalibration events, lower latency, completed human clinical trials, a regulatory pathway built for humanoid platforms, and training infrastructure that does not exist today. This is a story worth tracking closely, not one worth trading on yet.
The UC San Diego study is the first peer-reviewed demonstration that a teleoperated humanoid robot can complete a live surgical procedure, and it establishes a credible, early alternative to purpose-built surgical robotics. The system is not autonomous, is not yet validated in humans, and still struggles with recalibration and latency. What it establishes is technical feasibility, the floor a field must clear before clinical validation, regulatory clearance, and commercial deployment can begin.
Readers should watch three things next: human clinical trial announcements, partnerships between humanoid robotics companies and health systems, and early FDA guidance on whether surgical robot frameworks extend to humanoid platforms at all.
